Pacemaker tweak may ease heart failure by calming nerves

NCT ID NCT04573699

Completed Symptom relief Sponsor: BackBeat Medical Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a modified pacemaker in 34 people with heart failure (NYHA class II or III). The device delivers special pacing signals to reduce overactive sympathetic nerve activity, which can strain the heart. Researchers measured changes in arterial elastance, a sign of relaxed blood vessels, to see if the therapy worked safely during a short procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a modified pacemaker that delivers cardiac neuromodulation therapy (CNT) to calm overactive nerves
What this could lead to: If it works, this could lead to a new pacemaker-based therapy that helps heart failure patients feel better and live more comfortably.
What could go wrong: This was a small, early feasibility study with only 34 people, so results may not apply to everyone. The therapy is still experimental and needs much more testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE NYHA CLASS II are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mild heart failure moderate heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE NYHA CLASS II HEART FAILURE NYHA CLASS III

Contacts and locations

Locations

Silesian Center for Heart Diseases

Zabrze, 41-800, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.